Trial Profile
A retrospective study evaluating switching and discontinuation rates of apixaban, rivaroxaban or dabigatran therapy in patients with nonvalvular atrial fibrillationin in the US
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 May 2019
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb; Pfizer
- 22 May 2019 Results evaluating the association of switching to another oral anticoagulant vs. continuing with apixaban treatment among elderly patients with nonvalvular atrial fibrillation presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 13 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association